nonmem version 7.4 (ICON plc)
90
Structured Review
ICON plc
nonmem version 7.4
Nonmem Version 7.4, supplied by ICON plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nonmem+version+7%2E4/nonmem+version+7+3/pm39731592-50-6-12
Average 90 stars, based on 1 article reviews
Nonmem Version 7.4, supplied by ICON plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nonmem+version+7%2E4/nonmem+version+7+3/pm39731592-50-6-12
Average 90 stars, based on 1 article reviews
nonmem version 7.4 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen Article Snippet: This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets - A description of any restrictions on data availability - For clinical datasets or third party data, please ensure that the statement adheres to our policy Natasha Strydom X X X Microsoft Excel All analyses were conducted using Article Title: Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women Article Snippet: Population pharmacokinetic (PK) models for (i) rifapentine/desacetyl rifapentine and (ii) isoniazid were constructed using Article Title: Clinical decision support for chemotherapy-induced neutropenia using a hybrid pharmacodynamic/machine learning model. Article Snippet: PKPD models adapted from models reported in the literature were implemented and estimated in Article Title: Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma. Article Snippet: Objectives This study aimed to quantitatively evaluate the efficacy and safety of first-line systemic therapies for treating advanced hepatocellular carcinoma (aHCC).. Methods The study included clinical trials of first-line systemic therapies for aHCC since the approval of sorafenib in 2007.. Hazard function models were used to describe changes in overall survival (OS) and progression-free survival (PFS) over time. Article Title: Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia. Article Snippet: This report describes polysomnography and sleep diary exposure–response analyses from Study E2006-G000-304 (Study 304), a 1-month trial of 5or 10-mg lemborexant, zolpidem, or placebo; and Study E2006-G000-303 (Study 303), a 6-month trial of 5or 10-mg lemborexant or placebo.. Studies 304 and 303 included 1006 (86%) and 956 (68%) (female) participants, respectively; >40% were ≥65 years, with individual lemborexant exposures derived from a previously described pharmacokinetic model.. Linear mixed-effects analyses of polysomnography: latency to persistent sleep (LPS), sleep efficiency (SE), and wake after sleep onset (WASO) quantified the change from baseline given lemborexant exposure, time, and covariates, guided by consensus recommendations regarding clinical significance. Article Title: Early At-Home Measurement of Adalimumab Concentrations to Guide Anti-TNF Precision Dosing: A Pilot Study. Article Snippet: Background and Objective Underdosing of adalimumab can result in non-response and poor disease control in patients with rheumatic disease or inflammatory bowel disease.. In this pilot study we aimed to predict adalimumab concentrations with population pharmacokinetic model-based Bayesian forecasting early in therapy.. Methods Adalimumab pharmacokinetic models were identified with a literature search. Article Title: Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen Article Snippet: All analyses were conducted using Article Title: Evaluation of Ethnicity Effect on Intranasal Esketamine Pharmacokinetics by Population Pharmacokinetic Modeling Using Data From a Japanese Phase 2b Study. Article Snippet: Nonlinear mixed-effect modeling of concentrationtime data was performed using |